Drug Class Detail

Drug Class Chemotherapy - Alkylating

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Tinostamustine EDO-S101 Chemotherapy - Alkylating 14 HDAC Inhibitor 34 Tinostamustine (EDO-S101) comprises the structure of the DNA alkylating drug bendumustine combined with the pan-HDAC inhibitor vorinostat, which may both induce DNA damage and inhibit DNA repair resulting in increased tumor cell death (PMID: 28753594).
Fotemustine Chemotherapy - Alkylating 14
Mitomycin C Mitozytrex Chemotherapy - Alkylating 14 Mitomycin C is an antibiotic alkylating agent, which cross-links DNA to prevent DNA synthesis (NCI Drug Dictionary).
Trabectedin Yondelis Chemotherapy - Alkylating 14 Yondelis (trabectedin) is a marine-derived alkaloid that binds to DNA and induces DNA strand breaks, leading to cell cycle arrest and cell death in tumor cells (PMID: 24755886).
Cyclophosphamide Cytoxan CPM Chemotherapy - Alkylating 14 Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).
Dacarbazine Deticene Biocarbazine R Chemotherapy - Alkylating 14 Deticene (dacarbazine) alkylates and cross-links DNA, which disrupts the cell-cycle (NCI Drug Dictionary). Dacarbazine is FDA approved for melanoma (FDA.gov).
Ifosfamide Cyfos Z4942 Chemotherapy - Alkylating 14 Cyfos (ifosfamide) is an alkylating agent, which cross-links DNA, thereby inhibiting DNA replication (NCI Drug Dictionary).
Melflufen L-melphalanyl-p-L-fluorophenylalanine ethyl ester|mel-flufen Chemotherapy - Alkylating 14 Melflufen is a lipophilic alkylating agent that induces DNA damage, potentially resulting in increased tumor cell death (PMID: 27098276, PMID: 29029544).
Thiotepa Chemotherapy - Alkylating 14
Temozolomide Temodar Methazolastone Chemotherapy - Alkylating 14 Temodar (temozolomide) is a dacarbazine analog and cytotoxic alkylating agent (NCI Drug Dictionary).
Bendamustine Treanda Ribomustin|SyB L-0501|SDX-105 Chemotherapy - Alkylating 14 Treanda (bendamustine) is an alkylating agent with unique mechanisms, resulting in increased DNA damage and base-excision DNA repair pathway induction, and potentially leading to decreased growth of tumors, including those resistant to other alkylating agents (PMID: 18172283, PMID: 19117340, PMID: 19224851). Treanda (bendamustine) is FDA approved for use in chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma (FDA.gov).
Carmustine Becenun BCNU Chemotherapy - Alkylating 14 Becenun (carmustine) is an antineoplastic alkylating agent, which cross-links DNA and disrupts the cell-cycle (NCI Drug Dictionary).
Melphalan Alkeran Chemotherapy - Alkylating 14 Alkeran (melphalan) is an antineoplastic alkylating agent, which cross-links DNA and induces cell toxicity (NCI Drug Dictionary). Alkeran (melphalan) is FDA approved for multiple myeloma and epithelial ovarian carcinoma (FDA.gov).
Evofosfamide TH-302 Chemotherapy - Alkylating 14 Evofosfamide (TH-302) is a hypoxia-activated prodrug that releases a DNA-alkylating dibromo isophosphoramide mustard moiety within hypoxic regions of tumors, potentially providing antineoplastic activity with reduced systemic toxicity (NCI Drug Dictionary).
Molecular Profile Protein Effect Treatment Approaches